Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply

Kornelis S M van der Geest; Maria Sandovici; A Rutgers; Elisabeth Brouwer

doi:10.1093/rheumatology/keae261

Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply

Kornelis S M van der Geest^*
, Maria Sandovici
, A Rutgers
, Elisabeth Brouwer

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

68 Downloads (Pure)

Original language	English
Pages (from-to)	902-903
Number of pages	2
Journal	Rheumatology (Oxford, England)
Volume	64
Issue number	2
DOIs	https://doi.org/10.1093/rheumatology/keae261
Publication status	Published - Feb-2025

Access to Document

10.1093/rheumatology/keae261Licence: CC BY-NC

Comment on Immune checkpoint inhibitor-mediated polymyalgiaFinal publisher's version, 352 KBLicence: CC BY-NC

Handle.net

Persistent link

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement
Vermeulen, O. C. B., Brouwer, E., Slart, R. H. J. A., Sandovici, M., Rutgers, A., Hilterman, T. J., Hiddinga, B., Oosting, S. F., Jalving, M., de Heij, A. H., Knapen, D. G., Hospers, G. A. P. & van der Geest, K. S. M., Feb-2025, In: Rheumatology (Oxford, England). 64, 2, p. 771-779 9 p.
Research output: Contribution to journal › Erratum

Open Access
File
18 Citations (Scopus)

89 Downloads (Pure)

Cite this

@article{2d581096a11a4f6e8c96322e08b86ec1,

title = "Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply",

author = "\{van der Geest\}, \{Kornelis S M\} and Maria Sandovici and A Rutgers and Elisabeth Brouwer",

year = "2025",

month = feb,

doi = "10.1093/rheumatology/keae261",

language = "English",

volume = "64",

pages = "902--903",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "2",

}

Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply. / van der Geest, Kornelis S M ; Sandovici, Maria; Rutgers, A et al.
In: Rheumatology (Oxford, England), Vol. 64, No. 2, 02.2025, p. 902-903.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica

T2 - comparison of disease characteristics and treatment requirement. Reply

AU - van der Geest, Kornelis S M

AU - Sandovici, Maria

AU - Rutgers, A

AU - Brouwer, Elisabeth

PY - 2025/2

Y1 - 2025/2

U2 - 10.1093/rheumatology/keae261

DO - 10.1093/rheumatology/keae261

M3 - Comment/Letter to the editor

C2 - 38741187

SN - 1462-0324

VL - 64

SP - 902

EP - 903

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 2

ER -